What Changes When Screening Becomes the Standard

The gap no one was paid to close

Before a patient can be treated, or even counted, they have to be found. And an enormous number of patients with real, recognizable conditions are never found at all.

Underdiagnosis is usually explained as a knowledge problem, as if clinicians simply miss what’s in front of them. That’s rarely the real story. The conditions are recognizable; the screening just doesn’t happen consistently, because it takes time no one has and, for a long time, nothing rewarded doing it. The diagnosis gap is a systems gap, and systems gaps close when two things change: someone is paid to look, and looking becomes easy enough to do at scale.

What just changed: policy started paying for the look

The first of those changed this year. As of January 2026, CMS expanded a Medicare quality program to recommend tardive dyskinesia screening for every patient taking antipsychotic medications, the first time a federal quality program has formally recognized TD screening at all. It is a small policy line with a large signal behind it: screening for an underdiagnosed condition is now something the system measures and rewards, not just something clinicians are encouraged to remember.

That matters because incentives, far more than awareness campaigns, are what actually move screening rates. Tardive dyskinesia is a fitting test case. It affects roughly a quarter of patients on antipsychotics, the signs are observable, and a validated scale exists, and yet real-world recognition has long lagged, precisely because administering that scale to every patient every few months collides with the limits of a clinical day. The problem was never recognizing tardive dyskinesia. It was finding time to screen every patient for it.

Why the incentive alone isn’t enough

Here is where good policy meets an operational wall. Recommending that every antipsychotic patient be screened on a schedule is the right call, but the method most clinics have, a trained clinician administering a rating scale in a visit, is the same method that produced the gap in the first place. Ask an overloaded clinic to add a recurring assessment for a large patient population and screening rates will climb some, then stall against capacity, just as they always have.

An incentive changes the will. It does not, by itself, change the throughput. Universal screening needs a method that doesn’t consume a clinician’s scarce minutes for every patient, every cycle.

What objective, scalable screening changes

This is where objective screening earns its place. A short, video-based assessment a patient can complete on their own device, no app, no login, applies one consistent standard to everyone and doesn’t depend on a clinician finding time to administer a scale. It makes universal screening actually feasible: the population gets covered, the measure is the same for every patient, and a positive signal routes the person to appropriate clinical follow-up rather than disappearing.

TDScreen, Videra Health’s in-market TD screener, is the concrete example, an objective, device-agnostic assessment built for exactly the population the new CMS guidance describes. But the point isn’t one tool for one condition. It’s the shape of the solution: when an objective screen removes the capacity ceiling, a screening incentive can finally translate into patients found.

The model generalizes

Tardive dyskinesia is the case that happens to have both pieces in place right now, a fresh incentive and a validated objective screen. The more durable idea is that this pairing is repeatable. Plenty of conditions are underdiagnosed for the same structural reason: no consistent screening, no reward for doing it, no scalable method. As policy increasingly ties quality and value to whether at-risk patients are identified, the conditions that get a policy tailwind will be the ones where objective, scalable screening is ready to meet it.

For a life-sciences organization whose patients are going undiagnosed, that reframes screening from a nice-to-have into infrastructure, a way to close a genuine unmet-need gap at population scale and route identified patients toward care. The framing stays there, on unmet need and access; nothing here is about influencing what anyone prescribes.

Getting ahead of the next incentive

Screening is starting to count. For the first time, closing the diagnosis gap has landed on Medicare’s quality scorecard, and tardive dyskinesia is unlikely to be the last condition to get there. When an inconsistent, capacity-limited human process is replaced by an objective one that scales, whether a patient gets found stops depending on whether someone had the time to look. The organizations making objective screening routine now, while TD is the case with both an incentive and a ready method, are the ones positioned to move quickly when the next condition follows.

To see how objective, video-based screening is built and deployed as pharma-sponsored infrastructure, explore Videra Health’s Life Sciences solutions.